Prothena to Participate in the 36th Annual J.P. Morgan Healthcare Conference
January 03 2018 - 3:05PM
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical
biotechnology company focused on the discovery, development and
commercialization of novel therapies in the neuroscience and orphan
categories, today announced that members of its senior management
team will present and participate in the 36th Annual J.P. Morgan
Healthcare Conference on January 10th at 8:30 AM PT in San
Francisco, CA.
A live webcast of the company presentation can
be accessed through the Investors section of the Company's website
at www.prothena.com. Following the live presentation, a replay of
the webcast will be available on the Company's website for at least
90 days following the presentation date.
About Prothena
Prothena Corporation plc is a global, late-stage
clinical biotechnology company establishing fully integrated
research, development and commercial capabilities and focused on
advancing new therapies in the neuroscience and orphan categories.
Fueled by its deep scientific understanding built over decades of
research in protein misfolding, Prothena seeks to fundamentally
change the course of grave or currently untreatable diseases
associated with this biology. Prothena’s pipeline of antibody
therapeutic candidates targets a number of indications including AL
amyloidosis (NEOD001), Parkinson’s disease and other related
synucleinopathies (PRX002/RG7935) and ATTR amyloidosis (PRX004).
The Company continues discovery of additional novel therapeutic
candidates where its deep scientific understanding of disease
pathology can be leveraged. For more information, please visit the
Company's website at www.prothena.com.
Media & Investor
Contact:
Ellen Rose, Head of Communications650-922-2405,
ellen.rose@prothena.com
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Apr 2024 to May 2024
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From May 2023 to May 2024